Marie-Paul Lachaud
Keine laufenden Positionen mehr
Profil
Marie-Paul Lachaud worked as the Head of Business and Product Development Europe at Aratana Therapeutics, Inc. She holds a doctorate degree from Université Paris 1 Panthéon-Sorbonne and an undergraduate degree from École Nationale Vétérinaire d'Alfort.
Ehemalige bekannte Positionen von Marie-Paul Lachaud
| Unternehmen | Position | Ende |
|---|---|---|
| ARATANA THERAPEUTICS INC | Corporate Officer/Principal | - |
Ausbildung von Marie-Paul Lachaud
| École Nationale Vétérinaire d'Alfort | Undergraduate Degree |
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Aratana Therapeutics, Inc.
 Aratana Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aratana Therapeutics, Inc. engages in the development and commercialization of pet therapeutics. Its portfolio includes NOCITA, ENTYCE, and GALLIPRANT. NOCITA (bupivacaine liposome injectable suspension) acts as a local post-operative analgesia for cranial cruciate ligament surgery in dogs, and as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats. ENTYCE(capromorelin oral solution) is intended for appetite stimulation in dogs. GALLIPRANT (grapiprant tablets) is for the control of pain and inflammation associated with osteoarthritis in dogs. The company was founded by Linda Rhodes and Steven St. Peter on December 1, 2010 and is headquartered in Leawood, KS. | Health Technology |
